title: [Correlations between the hypothalamo-pituitary-adrenal axis and the metabolic syndrome].
abstract: The metabolic syndrome has several similarities with Cushing's syndrome (impaired glucose tolerance, hypertension, dyslipidemia, central obesity) suggesting that abnormalities in the regulation of the hypothalamic-pituitary-adrenal axis may have a link with the metabolic syndrome. Several studies suggested an association between the clinical signs of the metabolic syndrome and the increased hypothalamic-pituitary-adrenal axis activity based on increased cortisol concentration at 09.00 a.m. and increased cortisol response to corticotropin. According to the Barker hypothesis the fetal malnutrition could determine adult cardiovascular diseases (coronary heart disease, hypertension), some endocrine and metabolic disorders (obesity, type 2 diabetes and hyperlipidemia). The suggested mechanism of the phenomenon is that the suboptimal fetal nutrition results in glucocorticoid overproduction. The 11beta-hydroxysteroid dehydrogenase (converts biological inactive cortisone to cortisol and vice versa) is an important enzyme in cortisol metabolism. The increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in fat tissue could lead to central obesity and impaired glucose tolerance. The hypothesis that increased corticotropin-releasing hormone production drives the overactive hypothalamo-pituitary-adrenal axis was not proven. Further investigations are needed to identify additional pathogenetic factors and to find new therapeutic possibilities.
authors.affiliation: Országos Gyógyintézeti Központ, Belgyógyászati Osztály, Endokrinológiai Szakprofil, Budapest. goth@ogyik.hu
authors.forename: Miklós
authors.initials: M
authors.lastname: Góth
authors.forename: Erika
authors.initials: E
authors.lastname: Hubina
authors.forename: Márta
authors.initials: M
authors.lastname: Korbonits
mesh_terms: D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000378:metabolism; D000273:Adipose Tissue / Q000201:enzymology; D000310:Adrenal Gland Neoplasms / Q000150:complications / Q000503:physiopathology; D000324:Adrenocorticotropic Hormone / Q000096:biosynthesis; D000328:Adult; D000818:Animals; D001724:Birth Weight; D003327:Coronary Disease / Q000209:etiology / Q000401:mortality; D003348:Cortisone / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000209:etiology; D048070:Fetal Nutrition Disorders / Q000150:complications* / Q000378:metabolism; D015971:Gene Expression Regulation, Enzymologic; D005951:Glucose Tolerance Test; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism*; D006949:Hyperlipidemias / Q000209:etiology; D006973:Hypertension / Q000209:etiology; D007030:Hypothalamo-Hypophyseal System / Q000378:metabolism / Q000503:physiopathology*; D007226:Infant Mortality; D007231:Infant, Newborn; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology*; D008875:Middle Aged; D009765:Obesity / Q000209:etiology; D010913:Pituitary-Adrenal System / Q000378:metabolism / Q000503:physiopathology*; D015995:Prevalence
chemical_list: D000324:Adrenocorticotropic Hormone; D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1; D003348:Cortisone; D006854:Hydrocortisone